Effectiveness and safety of «Nifuroxazide-ECO» in therapy of escherichioses in children

In conditions of increasing antibiotic resistance and widespread antibiotic-associated diarrhea caused by Clostridium difficile, it is necessary to choose a rational drug for the empirical treatment of escherichioses, which has a wide range of antibacterial activity and does not lead to the development of serious side effects and disruption of the gut microbiota. The aim of the study is to assess the effectiveness and safety of the use of the drug “Nifuroxazid-ECO” in the integrated therapy of escherichioses in children. Patients and methods: 50 patients aged 1 month to 18 years were selected for work by random sampling, hospitalized in the intestinal department of the Pediatric Research and Clinical Center for Infectious Diseases of Russia with non-severe clinical forms of escherichioses. All patients underwent routine clinical, biochemical, instrumental examination. DNA detection of the pathogen was carried out by molecular methods in fecal samples using a set of reagents to detect and differentiate the DNA of diaregenic E. coli in environmental objects and clinical material by polymerase chain reaction (PCR) with hybridization-fluorescent detection. Patients received the drug “Nifuroxazid-ECO”at age dosage, every 6–8 hours for 5–7 days. Results: Against the background of the therapy, a significant majority of patients showed clinical improvement. The average duration of hospitalization was 4.8 days, the duration of preservation of diarrhoeal syndrome was 3.4 days. The drug showed good tolerability. There were no cases of antibiotic-associated diarrhea, re-hospitalization at an early date after treatment, serious adverse reactions. Conclusion: Studies have shown that the drug “Nifuroxazid- ECO” is a safe and effective modern drug which can be successfully used in the therapy of non-severe escherichioses in children.